En español
NIDA

Menu

Publications

Quick Links

Maryland Opioid Summary

Revised March 2019

Opioid-Related Overdose Deaths

In 2017, there were 1,985 overdose deaths­­­ involving opioids in Marylanda rate of 32.2 deaths per 100,000 persons, which is twofold greater than the national rate of 14.6 deaths per 100,000 persons. The state ranks in the top 5 for opioid-related overdose death rates with the largest increase attributed to cases involving synthetic opioids (mainly fentanyl).

From 2012 to 2017, the number of deaths involving synthetic opioids rose from 52 to 1,542 deaths (Figure 1). Heroin involved overdose deaths recently dropped to 522 in 2017 after a dramatic increase from 173 deaths in 2012 to 650 in 2016. Drug overdose deaths involving prescription opioids also recently declined to 711 in 2017.

See text Figure 1. Number of overdose deaths involving opioids in Maryland, by opioid category. Source: CDC WONDER.

Opioid Pain Reliever Prescriptions

In 2017, Maryland providers wrote 51.7 opioid prescriptions for every 100 persons (Figure 2). This was among the lowest prescribing rates in the country and less than the average U.S. rate of 58.7 prescriptions (CDC). 

While the rate of overdose deaths involving opioid prescriptions recently declined from 13.1 in 2016 to 11.5 deaths in 2017, the overall trend rose through 2016 (Figure 2).

See text Figure 2. Maryland rate of overdose deaths involving prescriptions opioids and the opioid prescribing rate. Source: CDC and CDC WONDER.

Neonatal Abstinence Syndrome (NAS)

NAS or neonatal opioid withdrawal syndrome (NOWS) may occur when a pregnant woman uses drugs such as opioids during pregnancy. A recent national study showed a fivefold increase in the incidence of NAS/NOWS between 2004 and 2014, from 1.5 cases per 1,000 hospital births to 8.0 cases per 1,000 hospital births ― that is one baby born with NAS/NOWS every 15 minutes in the United States. During the same period, hospital costs for NAS/NOWS births increased from $91 million to $563 million, after adjusting for inflation (Figure 3). In Maryland, 1,419 cases of NAS/NOWS were reported in 2015, the most recent data available for the state (Baltimore Sun).

See text Figure 3. NAS/NOW Incidence Rate and Hospital Costs for Treatment in the United States. Source: T.N.A. Winkelman, et al., 2018.

HIV Prevalence and HIV Diagnoses Attributed to Injection Drug Use (IDU)

See textFigure 4. Maryland: Estimated percent of male vs. female with new HIV diagnoses, by transmission category, 2016. Source: CDC and www.AIDSVU.org.
  • U.S. Incidence: In 2016, 9 percent (3,480) of the 39,589 new diagnoses of HIV in the United States were attributed to IDU. Among new cases, 6.3 percent (2,530) were transmitted via IDU or male-to-male contact and IDU among men and 2.3 percent (950) were transmitted via IDU among women (CDC).
  • U.S. Prevalence: In 2016, 991,447 Americans were living with a diagnosed HIV infection—a rate of 306.6 cases per 100,000 persons. Among males, 19.9 percent (150,466) contracted HIV from IDU or male-to-male contact and IDU while 21 percent (50,154) of females were living with HIV attributed to IDU (CDC).
  • State Incidence: Of the new HIV cases in 2016, 1,097 occurred in Maryland. Among males, 6.5 percent of new HIV cases were attributed to IDU or male-to-male contact and IDU. Among females, 8.1 percent of new HIV cases were attributed to IDU (Figure 4) (AIDSVu).
  • State Prevalence: In 2015, an estimated 33,072 persons were living with a diagnosed HIV infection in Maryland—a rate of 657 cases per 100,000 persons. Of those, 24.5 percent of male cases were attributed to IDU or male-to-male contact and IDU. Among females, 24.0 percent were living with HIV attributed to IDU (AIDSVu).

Hepatitis C (HCV) Prevalence and HCV Diagnoses Attributed to Injection Drug Use1

  • U.S. Incidence: In 2016, there were an estimated 41,200 new cases of acute HCV2 (CDC). Among cases reports that contain information about IDU, 68.6 percent indicated use of injection drugs (CDC).
  • U.S. Prevalence: An estimated 2.4 million Americans are living with HCV based on 2013-2016 annual averages (CDC).
  • State Incidence: There were approximately 35 new cases of acute HCV (0.6 per 100,000 persons) reported in Maryland in 2016 (CDC).
  • State Prevalence: In Maryland, there are an estimated 41,100 persons living with Hepatitis C (2013-2016 annual average), a rate of 890 cases per 100,000 persons (HepVu).

The National Institute of Health Funds Center of Excellence in Pain Education

This is the logo for the NIH Pain Consortium: Centers of Excellence in Pain Education.

Maryland is home to one of the eleven Centers of Excellence in Pain Education (CoEPEs): The Johns Hopkins University Center of Excellence in Pain Education. The CoEPEs act as hubs for the development, evaluation, and distribution of pain management curriculum resources for medical, dental, nursing, pharmacy and other schools to improve how health care professionals are taught about pain and its treatment.

Notes

  1. Not all states collect or report data on the incidence or prevalence of Hepatitis C or on how Hepatitis C is transmitted. When available, the data will be included.
  2. Actual acute cases estimated to be 13.9 times the number of reported cases in any year.

This page was last updated March 2019

Get this Publication

Opioid Summaries by State

NIH HEAL (Helping to End Addiction Long-term) Initiative

New Opioid Overdose Materials for Patients

Easy-to-read Drug Facts

This Is NIDA: Opioids

This Is NIDA: Opioids

The National Institute on Drug Abuse's research-based, informative video series "This Is NIDA," addresses the topic of OPIOIDS.